Biochemistry & Physiology: Open Access
Open Access

Mitochondrial dysfunction; Oxidative stress; Neurodegeneration; Cardiovascular disease; Aging; Cancer; Metabolic diseases; Inflammation; Therapeutic targets; Bioenergetics

Introduction

Mitochondrial dysfunction is emerging as a critical and pervasive factor in the development and progression of a wide array of human diseases. This fundamental cellular anomaly impacts crucial processes like cellular metabolism and immune responses, establishing itself as a central regulator of overall cellular health and disease states. Across various chronic inflammatory conditions, for instance, altered bioenergetics, heightened Reactive Oxygen Species (ROS) production, and impaired mitophagy are key intricate mechanisms that collectively drive the perpetuation of inflammation and significant tissue damage [1].

In the realm of cardiovascular diseases, encompassing conditions such as heart failure and atherosclerosis, mitochondrial dysfunction is recognized as a central mechanistic contributor. Specific molecular pathways, including impaired ATP production, increased oxidative stress, and dysregulated calcium handling, are observed to significantly contribute to the development and severity of cardiac pathology. Consequently, exploring and implementing emerging therapeutic interventions specifically targeting mitochondrial health holds considerable promise for improving cardiovascular outcomes [2].

Similarly, the complex process of aging and the onset of numerous age-related pathologies are critically driven by a decline in mitochondrial function. Molecular mechanisms, such as compromised mitochondrial biogenesis, altered mitochondrial dynamics, and impaired quality control, are known to contribute directly to cellular senescence and widespread tissue degeneration. Restoring optimal mitochondrial health through targeted therapeutic strategies presents a compelling approach to combat the various facets of aging [3].

Furthermore, chronic liver diseases, including prevalent conditions like non-alcoholic fatty liver disease (NAFLD) and viral hepatitis, illustrate mitochondrial dysfunction's critical role in their progression. Impaired mitochondrial function, characterized by oxidative phosphorylation defects and increased generation of Reactive Oxygen Species (ROS), contributes substantially to hepatocellular damage, chronic inflammation, and the process of fibrogenesis. This deeper understanding offers crucial insights into potential mitochondria-targeted therapeutic strategies aimed at liver protection and regeneration [4].

The intricate neurological system is particularly vulnerable to the detrimental effects of mitochondrial compromise. Mitochondrial dysfunction critically exacerbates neuroinflammation and acts as a primary driver of neurodegeneration across a spectrum of neurological disorders. Compromised mitochondrial integrity, altered dynamics, and diminished bioenergetics collectively contribute to the activation of microglia, astrogliosis, and ultimately, neuronal cell death. Emphasizing therapeutic approaches that target mitochondrial health could therefore unlock significant new avenues for treating these devastating conditions [5].

This pattern is also profoundly observed in kidney diseases, where mitochondrial dysfunction is intimately implicated in both the initiation and progression of conditions such as acute kidney injury and chronic kidney disease. Impaired mitochondrial bioenergetics, excessive oxidative stress, and dysregulated mitophagy are identified as key contributors to renal cell damage and fibrosis, strongly suggesting that therapeutic interventions aimed at enhancing mitochondrial function hold substantial promise for improving overall kidney health and prognosis [6].

Parkinson’s Disease (PD) serves as a compelling example, highlighting the central and complex role of mitochondrial dysfunction. It acts as a crucial link between genetic predispositions and environmental factors in the disease's etiology. Specifically, impaired mitochondrial quality control, compromised bioenergetics, and increased oxidative stress are collective factors that contribute to the progressive degeneration of dopaminergic neurons. Developing targeted therapeutic strategies focused on restoring mitochondrial health could therefore offer a vital pathway to slow or even halt the progression of PD [7].

Beyond specific organ systems, mitochondrial dysfunction is deeply intertwined with oxidative stress in the pathogenesis of various widespread metabolic diseases. Conditions such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease are characterized by compromised mitochondrial bioenergetics and excessive Reactive Oxygen Species (ROS) production, which together powerfully drive metabolic dysregulation. Identifying these key therapeutic targets and understanding their clinical implications is essential for developing interventions that improve patient outcomes in these pervasive conditions [8].

Even in the context of acute critical illnesses, mitochondrial dysfunction has been identified as a critical contributor. In Acute Respiratory Distress Syndrome (ARDS), for instance, impaired mitochondrial bioenergetics, excessive Reactive Oxygen Species (ROS) production, and dysregulated mitochondrial quality control mechanisms are major factors contributing to alveolar epithelial cell damage, inflammation, and pulmonary edema. Exploring potential mitochondria-targeted therapies offers a promising avenue to significantly improve ARDS outcomes and patient survival [9].

Finally, the complex and multifaceted role of mitochondrial dysfunction extends profoundly into cancer biology. It influences every aspect, from tumor initiation and progression to metastasis and the development of therapeutic resistance. Altered mitochondrial metabolism, dynamics, and apoptosis pathways all contribute significantly to the established hallmarks of cancer, strongly suggesting that targeting mitochondrial vulnerabilities offers highly promising avenues for the development of novel anti-cancer strategies [10].

This incredibly broad and fundamental impact across such diverse pathologies unequivocally underscores the mitochondria's foundational importance in maintaining cellular health and its pivotal role in disease pathogenesis.

Description

Mitochondrial dysfunction, a state of impaired mitochondrial function, underpins a vast spectrum of human diseases, extending from chronic inflammatory conditions to acute critical illnesses and age-related pathologies. This critical imbalance in cellular bioenergetics and redox homeostasis significantly impacts how cells respond to stress and maintain their integrity. In chronic inflammatory diseases, for example, the mitochondria's central role as a regulator of cellular metabolism and immune responses means that altered bioenergetics, an increase in Reactive Oxygen Species (ROS), and impaired mitophagy—the selective degradation of damaged mitochondria—all contribute to the ongoing perpetuation of inflammation and consequent tissue damage [1].

The impact of compromised mitochondria is particularly evident in metabolic and cardiovascular health. In cardiovascular diseases, fundamental issues like impaired ATP production, which is crucial for heart muscle contraction, increased oxidative stress, leading to cellular damage, and dysregulated calcium handling, which affects cardiac rhythm and contractility, are direct consequences of mitochondrial dysfunction that contribute to widespread cardiac pathology [2]. Similarly, the intertwined nature of mitochondrial dysfunction and oxidative stress is a cornerstone of various metabolic diseases, including obesity, type 2 diabetes, and non-alcoholic fatty liver disease. Here, compromised mitochondrial bioenergetics and excessive Reactive Oxygen Species (ROS) production act as primary drivers of systemic metabolic dysregulation [8]. The liver itself is profoundly affected, with impaired mitochondrial function, such as oxidative phosphorylation defects and elevated Reactive Oxygen Species, contributing to hepatocellular damage, inflammation, and fibrogenesis in chronic liver diseases like NAFLD and viral hepatitis [4].

Neurological and renal systems are also highly dependent on healthy mitochondrial function, making them particularly susceptible to dysfunction. In the brain, mitochondrial dysfunction plays a critical role in exacerbating neuroinflammation and driving neurodegeneration across numerous neurological disorders. Compromised mitochondrial integrity, dynamics, and bioenergetics contribute to detrimental processes like microglial activation, astrogliosis, and ultimately, neuronal cell death [5]. This is vividly illustrated in Parkinson’s Disease, where genetic factors and environmental influences converge to impair mitochondrial quality control and bioenergetics, leading to heightened oxidative stress and the specific degeneration of dopaminergic neurons, a hallmark of the condition [7]. The kidneys, too, show significant vulnerability, with impaired mitochondrial bioenergetics, excessive oxidative stress, and dysregulated mitophagy being key factors that contribute to renal cell damage and fibrosis in acute kidney injury and chronic kidney disease [6].

Mitochondrial dysfunction is also a key player in the aging process and the development of related pathologies. As organisms age, molecular mechanisms such as impaired mitochondrial biogenesis, which is the process of creating new mitochondria, altered mitochondrial dynamics, referring to the fusion and fission events that maintain mitochondrial networks, and compromised quality control systems all contribute to cellular senescence and progressive tissue degeneration [3]. These systemic cellular declines contribute to the vulnerability to many age-associated diseases.

Beyond chronic conditions and aging, mitochondrial dysfunction contributes significantly to acute critical states. In Acute Respiratory Distress Syndrome (ARDS), for instance, impaired mitochondrial bioenergetics, excessive Reactive Oxygen Species (ROS) production, and dysregulated mitochondrial quality control mechanisms are instrumental in causing alveolar epithelial cell damage, inflammation, and pulmonary edema [9]. This highlights how immediate, severe health crises can also stem from mitochondrial compromise.

Finally, the pervasive influence of mitochondrial dysfunction extends to cancer biology, where it plays a complex and multifaceted role. This includes its involvement in tumor initiation, progression, metastasis, and the development of resistance to therapeutic interventions. Altered mitochondrial metabolism, aberrant dynamics, and dysfunctional apoptosis pathways are critical contributors to the various hallmarks of cancer, demonstrating that targeting these mitochondrial vulnerabilities could offer innovative avenues for novel anti-cancer strategies [10]. The widespread involvement of mitochondrial dysfunction across such diverse pathologies underscores its fundamental importance in cellular health and disease, presenting a broad landscape for therapeutic intervention.

Conclusion

Mitochondrial dysfunction is a pervasive and critical factor in the pathogenesis of a wide range of human diseases. This fundamental cellular impairment acts as a central regulator of metabolism and immune responses, contributing to the development and progression of diverse conditions, from chronic inflammation and cardiovascular disease to neurodegeneration, metabolic disorders, and cancer. Across these pathologies, specific mechanisms often include altered mitochondrial bioenergetics, an increase in Reactive Oxygen Species (ROS) production, impaired mitochondrial quality control (such as compromised mitophagy or defective biogenesis), and dysregulated calcium handling. These profound mitochondrial defects collectively drive core pathological processes like persistent inflammation, extensive tissue damage, cellular senescence, and systemic metabolic dysregulation across various organ systems. For instance, in chronic inflammatory diseases, chronic liver conditions, and kidney pathologies, excessive ROS production and significant bioenergetic deficits are identified as key contributors. In neurological disorders, compromised mitochondrial integrity and dynamics are directly linked to neuroinflammation and neuronal cell death, as seen in Parkinson's Disease. Similarly, both the aging process and various metabolic diseases are significantly characterized by a breakdown in mitochondrial function, leading to systemic cellular and physiological decline. Even in acute critical conditions such as Acute Respiratory Distress Syndrome (ARDS), mitochondrial compromise substantially fuels the underlying pathology. The multifaceted role of mitochondrial dysfunction extends even further into cancer biology, where altered mitochondrial metabolism and dynamics critically influence tumor initiation, progression, metastasis, and the development of therapeutic resistance. Understanding these core, intricate mechanisms unequivocally underscores the mitochondria's pivotal role in maintaining cellular health and highlights its significant potential as a broad and promising therapeutic target across numerous devastating human conditions.

References

1. Xiaohui H, Jingjing H, Yunhui W (2023) Mitochondrial Dysfunction and Chronic Inflammatory Diseases: A Review.Oxid Med Cell Longev 2023:3959958.

   Indexed at, Google Scholar, Crossref

2. Jiani L, Yining S, Xiaosong L (2022) Mitochondrial dysfunction in cardiovascular disease: A comprehensive review of pathophysiology and therapeutic strategies.Front Cardiovasc Med 9:1045239.

   Indexed at, Google Scholar, Crossref

3. Sisi L, Yu H, Yuting C (2023) Mitochondrial dysfunction as a driver of aging and age-related diseases: Mechanisms and therapeutic opportunities.Ageing Res Rev 91:102078.

   Indexed at, Google Scholar, Crossref

4. Xiaohui W, Mengting C, Yiting G (2023) Mitochondrial Dysfunction and Chronic Liver Diseases: A Pathophysiological and Therapeutic Perspective.Cells 12:1618.

   Indexed at, Google Scholar, Crossref

5. Lu L, Weizhong Z, Yuhong W (2024) Mitochondrial dysfunction: A key player in neuroinflammation and neurodegeneration.Front Cell Neurosci 18:1365313.

   Indexed at, Google Scholar, Crossref

6. Jingjing L, Lingzhi F, Qingwei Z (2023) Mitochondrial Dysfunction and Kidney Diseases: A Pathophysiological Perspective.Int J Mol Sci 24:11627.

   Indexed at, Google Scholar, Crossref

7. Rui S, Haoxuan S, Jie D (2023) Mitochondrial dysfunction in Parkinson's disease: From genetics to therapeutic strategies.Brain Res Bull 201:110756.

   Indexed at, Google Scholar, Crossref

8. Yuqin Y, Yanyan D, Xiaojuan Z (2022) Mitochondrial dysfunction and oxidative stress in metabolic diseases: Therapeutic targets and clinical implications.J Biomed Sci 29:104.

   Indexed at, Google Scholar, Crossref

9. Xiaoxiao Y, Weiyi L, Zhengyu J (2023) Mitochondrial dysfunction in acute respiratory distress syndrome: Mechanisms and therapeutic strategies.Front Pharmacol 14:1222477.

   Indexed at, Google Scholar, Crossref

10. Yining L, Hao Z, Xiaomin Z (2022) Mitochondrial dysfunction and its role in cancer progression and therapy.Front Oncol 12:981143.

    Indexed at, Google Scholar, Crossref